Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $20.00M |
| Gross Profit (TTM) | $20.00M |
| EBITDA | $-131.89M |
| Operating Margin | -132.80% |
| Return on Equity | -38.70% |
| Return on Assets | -22.30% |
| Revenue/Share (TTM) | $0.41 |
| Book Value | $6.93 |
| Price-to-Book | 4.65 |
| Price-to-Sales (TTM) | 77.15 |
| EV/Revenue | 64.82 |
| EV/EBITDA | 6.14 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $55.34M |
| Float | $37.25M |
| % Insiders | 1.46% |
| % Institutions | 96.53% |
Volatility is currently expanding
The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Maze Therapeutics, Inc. (MAZE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will participate in two upcoming investor conferences:
Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late 2026 or early 2027 Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD on track to initiate in 2026 Strong balance sheet with $528 million in cash, cash equivalents and marketable securities; inclusive of net proceeds from the $150 million registered offering and $20 million MZE001 milestone payment in April 2026; cash runway expected to extend into 2029 SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the first quarter ended March 31, 2026, highlighting recent progress and business updates.
SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze.
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Maze Therapeutics, Inc. (NASDAQ: MAZE). The investigation focuses on Maze's executive officers and whether investor losses may be recovered under federal securities laws.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MAZE and any ticker you trade — then tracks every position and per-strategy win rate.
